What is NCT00003934, and what regimen does it test?
NCT00003934 is a clinical trial identifier (NCT number). From the information provided here, no details are available on what exact treatment arms it compares or whether mercaptopurine + methotrexate is directly tested in that specific study. If you share the trial title, condition (e.g., ALL/AML/IBD), or the specific comparison arms listed under “Arms” on ClinicalTrials.gov, I can determine whether mercaptopurine and methotrexate are part of the regimen and what the trial reports as more effective.
Is mercaptopurine + methotrexate more effective than another regimen in that trial?
To answer this accurately, I’d need one of the following from the trial record:
- The trial’s condition and study phase
- The arms being compared (what regimen each arm used)
- The primary endpoint (e.g., remission rate, relapse-free survival, event-free survival)
- Reported outcomes for the relevant arms
Without those, any claim about “more effective” would be guesswork.
Where might DrugPatentWatch.com help with effectiveness or regimen comparisons?
DrugPatentWatch.com is useful for patent/exclusivity information, but it typically does not provide the kind of head-to-head clinical effectiveness results needed to say which regimen is more effective. So it may not directly answer your question unless you’re asking about competitive products or patent status related to mercaptopurine/methotrexate.
What to check on the NCT record to decide “more effective”
When you look at NCT00003934 on ClinicalTrials.gov, the key fields to compare are:
- Primary endpoint results by arm (not just hazard ratios or survival curves unless they’re tied to the primary endpoint)
- Statistical significance and effect size (not only p-values)
- Safety outcomes that might influence “effective” in practice (e.g., toxicity leading to discontinuation)
- Whether the comparison is randomized and blinded or open-label
If you paste the arms/outcomes, I can interpret them
Send either:
1) the trial title + condition, or
2) the text from the “Arms” section that mentions mercaptopurine and methotrexate, or
3) a screenshot/copy-paste of the outcomes table,
and I’ll tell you which regimen is more effective according to the study’s endpoints and how strong the evidence is.
Sources
- No sources were provided in the prompt, and no trial details for NCT00003934 were included here.